Posted by Michael Wonder on 10 Aug 2021
Pear Therapeutics announces formulary availability for its three FDA authorised prescription digital therapeutics at OptumRx
10 August 2021 - OptumRx to make Pear’s three commercial prescription digital therapeutics accessible to patients with Optum formulary access.
Pear Therapeutics today announced formulary availability of its commercial products at OptumRx, Pear’s commercial products include the prescription digital therapeutics reSET and reSET-O for the treatment of substance use disorder and opioid used disorder, respectively, and Somryst for the treatment of chronic insomnia.
